DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Transactions / V•••••••
••• Locked
Add-on acquisitionannouncedadd-onannounced Feb 17, 2026Fact
What happened
- Target
- V•••••••
- Platform
- E•••••••• P•••••add-on basis: E•••••••• P•••••, a global specialty pharmaceutical company focused on delivering medicines to small, underserved or rare disease populations, has announced the acquisition of V•••••••® (iloprost trometamol) from B•••• A•, including rights to the accompanying Breelib® nebuliser delivery technology. | E•••••••• P••••• is held by G•••• C•••••• on its portfolio page; published on G•••• C••••••'s own news page
- Control
- Control
- Share acquired
- unknown
- Industry
- healthcare / pharma
- Target location
- unknown
- Seller kind
- Unknown
- Rollover
- unknown
Values, only where disclosed
- Enterprise value
- Not disclosed
- Purchase price
- Not disclosed
- Equity value
- Not disclosed
- Target revenue
- Not disclosed
- Target EBITDA
- Not disclosed
- Multiple
- Not disclosed
Parties and roles
5 named
Buy side
- “••• Locked”
- “••• Locked”
- “••• Locked”
Sell side
- “••• Locked”
Side not stated
- “••• Locked”
Evidence
“••• Locked”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 18, 2026